HYPERTENSION, DIABETES MELLITUS, AND BLOOD GROUPS IN BENIGN PROSTATIC HYPERTROPHY

1966 ◽  
Vol 38 (1) ◽  
pp. 18-23 ◽  
Author(s):  
J. B. BOURKE ◽  
J. P. GRIFFIN
2017 ◽  
Vol 11 ◽  
pp. S627-S630
Author(s):  
B. Shivananda Nayak ◽  
Khaleel Sinanan ◽  
Shivang Sharma ◽  
Vashista Shripat ◽  
Rukaiya Sidat ◽  
...  

1996 ◽  
Vol 63 (1) ◽  
pp. 77-80
Author(s):  
S. Guazzieri ◽  
W. Cecchetti ◽  
M. Meneguolo ◽  
G. D'incà ◽  
R. Bertoldin

— Laser treatment of benign prostatic hypertrophy (BPH) has gradually become more widespread over the last few years. In the USA it is considered an alternative to endoscopic resection as far as insurance payments are concerned. Different methods are used but the most common and suitable one for urologists is the removal and coagulation of the prostatic tissue under visual control (VLAP or ELAP). The Authors report their personal experience in this type of treatment where good results are due to: 1) combination of a powerful, stable laser source 2) durable side-emission contact fibre 3) laser resector, which also in the absence of epicystostomy maintains a good flow during the operation. However, “laser resection” should still be considered an experimental procedure to be used for randomised protocols or on selected patients (high risk of bleeding, Jehovah's witnesses, carriers of pace-maker, etc.).


1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.


1986 ◽  
Vol 70 (4) ◽  
pp. 359-363 ◽  
Author(s):  
H. Gregory ◽  
I. R. Willshire ◽  
J. P. Kavanagh ◽  
N. J. Blacklock ◽  
S. Chowdury ◽  
...  

1. High concentrations (272 ± 33 ng/ml) of urogastrone-epidermal growth factor were measured in prostatic fluid from normal males by a specific radioimmunoassay. 2. Significantly lower concentrations (155 ± 24 ng/ml) were observed in the prostatic fluid of patients with benign prostatic hypertrophy than in the age-matched normal controls (2P < 0.01). 3. The growth factor content of seminal fluid was accounted for by the contribution of prostatic fluid. 4. Immunochemical studies failed to show evidence of synthesis within the gland nor could high affinity receptors for the protein be demonstrated in membrane preparations of the gland.


Sign in / Sign up

Export Citation Format

Share Document